EPO and anemia: Similarly, the longer half-life of novel erythropoietin stimulating protein (NESP), which was created by the introduction of 2 extra N-linked carbohydrate addition sites into the primary sequence of EPO, is likely to afford it a clinical advantage over rhEPO by allowing less frequent dosing in patients treated for anemia [10].